Title

Picoplatin Derivatives for Anticancer Drug Development

Poster Number

12A

Lead Author Major

Biological Science

Lead Author Status

Freshman

Second Author Major

Biochemistry

Second Author Status

Freshman

Third Author Major

Biochemistry

Third Author Status

Sophomore

Fourth Author Major

Biochemistry

Fourth Author Status

Senior

Fifth Author Major

Biochemistry

Fifth Author Status

Junior

Format

Poster Presentation

Faculty Mentor Name

Qinliang Zhao

Faculty Mentor Email

qzhao@pacific.edu

Faculty Mentor Department

Chemistry

Graduate Student Mentor Name

Chao Feng

Graduate Student Mentor Email

c_feng1@u.pacific.edu

Graduate Student Mentor Department

Chemistry

Abstract/Artist Statement

Platinum-based complexes have been extensively investigated as chemotherapy drugs for multiple cancer types. Since the discovery of the first platinum drug cisplatin, another six platinum drugs have been approved for clinical use in USA and other countries. Cancer itself, however, is forever evolving, constantly producing cross resistance to the current medication. The chemotherapy drugs used in the past are soon becoming ineffective against tomorrow’s cancer. To discover new anticancer agents that can overcome the resistance and toxicity issues of the existing platinum drugs, a new family of platinum complexes are designed and synthesized based on Picoplatin, a platinum drug in clinical trials for solid tumors. More than 10 picoplatin derivatives with distinctive amine groups as non-leaving groups have been synthesized. All complexes were purified from either solvent washing, crystallization or chromatography. The platinum intermediates and final products were characterized using ESI-AccuTOF MS, HPLC, 1H NMR, 13C NMR, 195Pt NMR, and X-ray crystallography. Solubility of the platinum complexes in water and organic solvents was obtained using ICP-OES.

Location

DeRosa University Center Ballroom

Start Date

27-4-2018 12:30 PM

End Date

27-4-2018 2:30 PM

This document is currently not available here.

Share

COinS
 
Apr 27th, 12:30 PM Apr 27th, 2:30 PM

Picoplatin Derivatives for Anticancer Drug Development

DeRosa University Center Ballroom

Platinum-based complexes have been extensively investigated as chemotherapy drugs for multiple cancer types. Since the discovery of the first platinum drug cisplatin, another six platinum drugs have been approved for clinical use in USA and other countries. Cancer itself, however, is forever evolving, constantly producing cross resistance to the current medication. The chemotherapy drugs used in the past are soon becoming ineffective against tomorrow’s cancer. To discover new anticancer agents that can overcome the resistance and toxicity issues of the existing platinum drugs, a new family of platinum complexes are designed and synthesized based on Picoplatin, a platinum drug in clinical trials for solid tumors. More than 10 picoplatin derivatives with distinctive amine groups as non-leaving groups have been synthesized. All complexes were purified from either solvent washing, crystallization or chromatography. The platinum intermediates and final products were characterized using ESI-AccuTOF MS, HPLC, 1H NMR, 13C NMR, 195Pt NMR, and X-ray crystallography. Solubility of the platinum complexes in water and organic solvents was obtained using ICP-OES.